Deutsche Bank Maintains Buy on Roivant Sciences, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $14 to $15.
April 03, 2024 | 9:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deutsche Bank maintains a Buy rating on Roivant Sciences and increases the price target from $14 to $15.
The upgrade in price target by a reputable financial institution like Deutsche Bank typically signals a positive outlook on the company's future performance. This can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100